Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-12-11, Stock:ABBV, The news for the past five days is as follows:
2018-12-03: NEWS1: AbbVie Stock Could Become a New Happy Pill for Investors.NEWS2: IMBRUVICA® (ibrutinib) Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement in Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy of Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).NEWS3: XLV, PFE, MRK, ABBV: ETF Inflow Alert.NEWS4: XLV, PFE, MRK, ABBV: ETF Inflow Alert.NEWS5: AbbVie Settles With Pfizer for Humira Biosimilar in U.S..NEWS6: AbbVie Settles With Pfizer for Humira Biosimilar in U.S..NEWS7: AbbVie's Imbruvica Achieves Up to 7-Year Progression-Free Survival in Leukemia Patients.NEWS8: AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018.NEWS9: AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018.NEWS10: AbbVie Settles With Pfizer for Humira Biosimilar in U.S..NEWS11: AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018.NEWS12: Today's Research Reports on Trending Tickers: AbbVie and OPKO Health.
2018-12-04: NEWS1: AbbVie Falls 3%.NEWS2: Roche Announces Positive Data on Venclexta/Venclyxto at ASH.NEWS3: Roche Announces Positive Data on Venclexta/Venclyxto at ASH.NEWS4: Roche Announces Positive Data on Venclexta/Venclyxto at ASH.NEWS5: IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data at ASH 2018.NEWS6: JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial.NEWS7: JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial.NEWS8: AbbVie Stock Could Become a New Happy Pill for Investors.NEWS9: AbbVie Stock Could Become a New Happy Pill for Investors.
2018-12-06: NEWS1: AbbVie Stock Has a $10 Upside Opportunity — Buy It Now.NEWS2: AbbVie Stock Has a $10 Upside Opportunity — Buy It Now.NEWS3: AbbVie Falls 3%.NEWS4: AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study.NEWS5: AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study.NEWS6: AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study.NEWS7: AbbVie Stock Has a $10 Upside Opportunity — Buy It Now.NEWS8: The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering.
2018-12-07: NEWS1: A Look at AbbVie’s Earnings Projections for 2018.NEWS2: Assessing AbbVie’s 2018 Revenue Projections.NEWS3: Analysts’ Recommendations for AbbVie in December.NEWS4: AbbVie Falls 4%.NEWS5: [$$] Congress to Drug Makers: Why Stock Buybacks Over Lowered Drug Prices?.
2018-12-10: NEWS1: AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know.NEWS2: Don’t Punish Gilead Stock for Doing Its Job.NEWS3: Don’t Punish Gilead Stock for Doing Its Job.NEWS4: Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend.NEWS5: Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend.NEWS6: Don’t Punish Gilead Stock for Doing Its Job.NEWS7: Humira’s Biosimilar Competition in International Markets.NEWS8: Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend.NEWS9: Considering AbbVie’s 2018 Expense Projections.NEWS10: Exploring AbbVie’s Margin Projections for 2018.

Answer: Rise